Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Carcinoma, Renal Cell,Peritoneal Neoplasms,Ovarian Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Fallopian Tube Neoplasms, Date of authorisation: 14/01/2018, Revision: 4, Status: Authorised

2019 ◽  
Author(s):  
Keyword(s):  
Breast Neoplasms ◽  
Ovarian Neoplasms ◽  
Small Cell ◽  
Small Cell Lung ◽  
Assessment Report ◽  
Peritoneal Neoplasms ◽  
European Public ◽  
European Public Assessment Report ◽  
Fallopian Tube Neoplasms ◽  
Carcinoma Renal Cell
Sign in / Sign up

Export Citation Format

Share Document